AAV-mediated RLBP1 gene therapy improves the rate of dark adaptation in Rlbp1 knockout mice

Molecular Therapy Methods and Clinical Development

Volumn 2, Issue , 2015, Pages 15022-

  Choi, Vivian W ^a   Bigelow, Chad E ^a   McGee, Terri L ^a   Gujar, Akshata N ^a   Li, Hui ^a   Hanks, Shawn M ^a   Vrouvlianis, Joanna ^a   Maker, Michael ^a   Leehy, Barrett ^a   Zhang, Yiqin ^a   Aranda, Jorge ^a   Bounoutas, George ^a   Demirs, John T ^a   Yang, Junzheng ^a   Ornberg, Richard ^a   Wang, Yu ^a   Martin, Wendy ^b   Stout, Kelly R ^b   Argentieri, Gregory ^a   Grosenstein, Paul ^a   Diaz, Danielle ^a   Turner, Oliver ^a   Jaffee, Bruce D ^a   Police, Seshidhar R ^a   Dryja, Thaddeus P ^a   more..

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b ALCON RESEARCH LTD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENO ASSOCIATED VIRUS VECTOR; BEST1 PROTEIN; GREEN FLUORESCENT PROTEIN; PEPTIDES AND PROTEINS; RETINOID BINDING PROTEIN; RETINOID BINDING PROTEIN 1; RPE65 PROTEIN; UNCLASSIFIED DRUG; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DARK ADAPTATION; ELECTRORETINOGRAM; FEMALE; GENE EXPRESSION; GENE SEQUENCE; GENE THERAPY; MACACA FASCICULARIS; MALE; MOUSE; MUELLER CELL; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; QUALITATIVE ANALYSIS; REPORTER GENE; RETINA CELL; RETINAL PIGMENT EPITHELIUM; SEROTYPE; TARGET CELL; VIRUS CAPSID; VIRUS GENOME; DOSE RESPONSE; HUMAN; IMMUNOHISTOCHEMISTRY; PHOTOPIC VISION; PHOTORECEPTOR; RETINITIS PIGMENTOSA; VIRAL GENE THERAPY;

EID: 84984795753     PISSN: None     EISSN: 23290501     Source Type: Journal    
DOI: 10.1038/mtm.2015.22     Document Type: Article

References (26)

1. 1 Daiger, SP, Sullivan, LS, Bowne, SJ, Genes and mutations causing retinitis pigmentosa. Clin Genet 84 (2013), 132–141.
2. 2 Maw, MA, Kennedy, B, Knight, A, Bridges, R, Roth, KE, Mani, EJ, et al. Mutation of the gene encoding cellular retinaldehyde-binding protein in autosomal recessive retinitis pigmentosa. Nat Genet 17 (1997), 198–200.
3. 3 Eichers, ER, Green, JS, Stockton, DW, Jackman, CS, Whelan, J, McNamara, JA, et al. Newfoundland rod-cone dystrophy, an early-onset retinal dystrophy, is caused by splice-junction mutations in RLBP1. Am J Hum Genet 70 (2002), 955–964.
4. 4 Golovleva, I, Bhattacharya, S, Wu, Z, Shaw, N, Yang, Y, Andrabi, K, et al. Disease-causing mutations in the cellular retinaldehyde binding protein tighten and abolish ligand interactions. J Biol Chem 278 (2003), 12397–12402.
5. 5 He, X, Lobsiger, J, Stocker, A, Bothnia dystrophy is caused by domino-like rearrangements in cellular retinaldehyde-binding protein mutant R234W. Proc Natl Acad Sci U S A 106 (2009), 18545–18550.
6. 6 Burstedt, MS, Sandgren, O, Golovleva, I, Wachtmeister, L, Effects of prolonged dark adaptation in patients with retinitis pigmentosa of Bothnia type: an electrophysiological study. Doc Ophthalmol 116 (2008), 193–205.
7. 7 Travis, GH, Golczak, M, Moise, AR, Palczewski, K, Diseases caused by defects in the visual cycle: retinoids as potential therapeutic agents. Annu Rev Pharmacol Toxicol 47 (2007), 469–512.
8. 8 Wang, JS, Kefalov, VJ, An alternative pathway mediates the mouse and human cone visual cycle. Curr Biol 19 (2009), 1665–1669.
9. 9 Wang, JS, Kefalov, VJ, The cone-specific visual cycle. Prog Retin Eye Res 30 (2011), 115–128.
10. 10 Saari, JC, Nawrot, M, Kennedy, BN, Garwin, GG, Hurley, JB, Huang, J, et al. Visual cycle impairment in cellular retinaldehyde binding protein (CRALBP) knockout mice results in delayed dark adaptation. Neuron 29 (2001), 739–748.
11. 11 Pitz, S, Moll, R, Intermediate-filament expression in ocular tissue. Prog Retin Eye Res 21 (2002), 241–262.
12. 12 Bunt-Milam, AH, Saari, JC, Immunocytochemical localization of two retinoid-binding proteins in vertebrate retina. J Cell Biol 97 (1983), 703–712.
13. 13 Testa, F, Maguire, AM, Rossi, S, Pierce, EA, Melillo, P, Marshall, K, et al. Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital Amaurosis type 2. Ophthalmology 120 (2013), 1283–1291.
14. 14 Bainbridge, JW, Smith, AJ, Barker, SS, Robbie, S, Henderson, R, Balaggan, K, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 358 (2008), 2231–2239.
15. 15 Jacobson, SG, Cideciyan, AV, Ratnakaram, R, Heon, E, Schwartz, SB, Roman, AJ, et al. Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch Ophthalmol 130 (2012), 9–24.
16. 16 Vandenberghe, LH, Bell, P, Maguire, AM, Cearley, CN, Xiao, R, Calcedo, R, et al. Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey. Sci Transl Med, 3, 2011, 88ra54.
17. 17 Natkunarajah, M, Trittibach, P, McIntosh, J, Duran, Y, Barker, SE, Smith, AJ, et al. Assessment of ocular transduction using single-stranded and self-complementary recombinant adeno-associated virus serotype 2/8. Gene Ther 15 (2008), 463–467.
18. 18 Li, H, Poor, S, Bigelow, CE, Choi, VW, Hanks, S, Vrouvlianis, J, et al. A comparison of the effects of subretinal injection of scAAV2-CMV-GFP on retinal structure, visual function, and GFP expression by two injectors. Invest Ophthalmol Vis Sci ARVO E-abstract, 54, 2013, 2740.
19. 19 Kolesnikov, AV, Tang, PH, Parker, RO, Crouch, RK, Kefalov, VJ, The mammalian cone visual cycle promotes rapid M/L-cone pigment regeneration independently of the interphotoreceptor retinoid-binding protein. J Neurosci 31 (2011), 7900–7909.
20. 20 Acland, GM, Aguirre, GD, Ray, J, Zhang, Q, Aleman, TS, Cideciyan, AV, et al. Gene therapy restores vision in a canine model of childhood blindness. Nat Genet 28 (2001), 92–95.
21. 21 Rabinowitz, JE, Rolling, F, Li, C, Conrath, H, Xiao, W, Xiao, X, et al. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 76 (2002), 791–801.
22. 22 Lock, M, McGorray, S, Auricchio, A, Ayuso, E, Beecham, EJ, Blouin-Tavel, V, et al. Characterization of a recombinant adeno-associated virus type 2 Reference Standard Material. Hum Gene Ther 21 (2010), 1273–1285.
23. 23 Vogel, JS, Bullen, EC, Teygong, CL, Howard, EW, Identification of the RLBP1 gene promoter. Invest Ophthalmol Vis Sci 48 (2007), 3872–3877.
24. 24 McCarty, DM, Fu, H, Monahan, PE, Toulson, CE, Naik, P, Samulski, RJ, Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther 10 (2003), 2112–2118.
25. 25 Wenzel, A, Reme, CE, Williams, TP, Hafezi, F, Grimm, C, The Rpe65 Leu450Met variation increases retinal resistance against light-induced degeneration by slowing rhodopsin regeneration. J Neurosci 21 (2001), 53–58.
26. 26 Nork, TM, Murphy, CJ, Kim, CB, Ver Hoeve, JN, Rasmussen, CA, Miller, PE, et al. Functional and anatomic consequences of subretinal dosing in the cynomolgus macaque. Arch Ophthalmol 130 (2012), 65–75.